6 Participants Needed

Hyperpolarized Xenon-129 MRI for Idiopathic Pulmonary Fibrosis

(XeMRIIPF Trial)

RA
CB
Overseen ByCarol Bampoe, BS
Age: 18+
Sex: Any
Trial Phase: Phase < 1
Sponsor: University of Virginia
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Hyperpolarized Xenon-129 MRI for Idiopathic Pulmonary Fibrosis?

The research suggests that Hyperpolarized Xenon-129 MRI is promising for monitoring idiopathic pulmonary fibrosis because it can image how gas moves in the lungs without using harmful radiation. This method can help detect lung function issues and track disease progression, potentially improving diagnosis and treatment response assessment.12345

Is Hyperpolarized Xenon-129 MRI safe for humans?

Research indicates that Hyperpolarized Xenon-129 MRI has been studied for safety and tolerability, including in children with cystic fibrosis, suggesting it is generally safe for human use.13467

How is the treatment Hyperpolarized Xenon-129 MRI unique for idiopathic pulmonary fibrosis?

Hyperpolarized Xenon-129 MRI is unique because it uses inhaled xenon gas to create detailed images of lung function, allowing doctors to see how well gas is transferred from the airspaces to the blood. This provides a new way to assess lung health in idiopathic pulmonary fibrosis, which is different from traditional methods that don't offer such detailed regional information.138910

What is the purpose of this trial?

Idiopathic pulmonary fibrosis has a poor prognosis with limited treatment options. The Investigator hypothesize hyperpolarized Xe129-MRI can be performed in patients with IPF and repeated over time which will detect deficiencies related to perfusion in the lung.

Research Team

JK

John Kim, MD

Principal Investigator

University of Virginia

Eligibility Criteria

This trial is for adults diagnosed with Idiopathic Pulmonary Fibrosis who can consent to the study. It's not suitable for those with claustrophobia, metal implants, severe heart conditions, chronic kidney failure, cirrhosis, or those needing continuous oxygen. Pregnant or lactating individuals and those with recent respiratory infections are also excluded.

Inclusion Criteria

I have been diagnosed with idiopathic pulmonary fibrosis.
Able to provide informed consent

Exclusion Criteria

I can follow simple instructions and remain still for 10-15 seconds.
I don't have conditions or devices that prevent MRI scans.
I have had a heart attack, stroke, or my high blood pressure is not well controlled.
See 6 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo hyperpolarized Xe-129 MRI to assess pulmonary ventilation and perfusion

Up to 24 hours
1 visit (in-person)

Follow-up

Participants are monitored for changes in MRI indices over time

Up to 24 hours post MRI analysis

Treatment Details

Interventions

  • Hyperpolarized Xenon-129
Trial Overview The trial tests whether a type of lung imaging called Hyperpolarized Xenon-129 MRI can help detect changes in lung perfusion over time in patients with Idiopathic Pulmonary Fibrosis.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: IPF subjectsExperimental Treatment1 Intervention
IPF subjects will undergo Xe-129 MRI

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Virginia

Lead Sponsor

Trials
802
Recruited
1,342,000+

Findings from Research

Hyperpolarized xenon-129 MRI detected significant lung function impairments in patients with usual interstitial pneumonia (UIP), showing a ventilation defect fraction of 30% compared to 21% in healthy controls, indicating its efficacy in identifying lung abnormalities.
The MRI also revealed elevated levels of xenon dissolved in the lung interstitium in UIP patients, which could serve as an early indicator of lung fibrosis, even when traditional pulmonary function tests showed normal or mild impairment.
Hyperpolarized Xenon-129: A New Tool to Assess Pulmonary Physiology in Patients with Pulmonary Fibrosis.Qing, K., Altes, TA., Mugler, JP., et al.[2023]
The continuous flow-type hyperpolarizing (CF-HP) system allows for effective lung imaging using hyperpolarized (129)Xe MRI at very low concentrations of xenon, minimizing the anesthetic effects and reducing xenon consumption.
Using a 70% xenon gas mixture resulted in better signal-to-noise ratios for both gas and dissolved-phase images compared to a 3% mixture, although the apparent diffusion coefficient (ADC) was higher with the 3% mixture, indicating a complex relationship between concentration and imaging quality.
Hyperpolarized 129 Xe MRI of the mouse lung at a low xenon concentration using a continuous flow-type hyperpolarizing system.Wakayama, T., Kitamoto, M., Ueyama, T., et al.[2015]
Hyperpolarized 129Xe MRI effectively identifies functional impairment in patients with idiopathic pulmonary fibrosis (IPF), showing a significant increase in barrier uptake compared to healthy individuals, indicating its potential as a diagnostic tool.
The MRI metrics correlated strongly with pulmonary function tests (PFTs) but poorly with CT fibrosis scores, suggesting that 129Xe MRI may provide a more accurate assessment of lung function and disease progression in IPF patients.
Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis.Wang, JM., Robertson, SH., Wang, Z., et al.[2018]

References

Hyperpolarized Xenon-129: A New Tool to Assess Pulmonary Physiology in Patients with Pulmonary Fibrosis. [2023]
Hyperpolarized 129 Xe MRI of the mouse lung at a low xenon concentration using a continuous flow-type hyperpolarizing system. [2015]
Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis. [2018]
Hyperpolarised xenon-129 diffusion-weighted magnetic resonance imaging for assessing lung microstructure in idiopathic pulmonary fibrosis. [2023]
New Developments in Imaging Idiopathic Pulmonary Fibrosis With Hyperpolarized Xenon Magnetic Resonance Imaging. [2023]
Feasibility, tolerability and safety of pediatric hyperpolarized 129Xe magnetic resonance imaging in healthy volunteers and children with cystic fibrosis. [2022]
Standalone portable xenon-129 hyperpolariser for multicentre clinical magnetic resonance imaging of the lungs. [2023]
Transverse relaxation rates of pulmonary dissolved-phase Hyperpolarized 129 Xe as a biomarker of lung injury in idiopathic pulmonary fibrosis. [2021]
The role of hyperpolarized 129xenon in MR imaging of pulmonary function. [2018]
10.United Statespubmed.ncbi.nlm.nih.gov
Repeatability of regional pulmonary functional metrics of Hyperpolarized 129 Xe dissolved-phase MRI. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security